Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Double-Blind Randomized Clinical Trial of the Efficacy of Venlafaxine Versus Citalopram in the Treatment of the Acute Phase of Major Depressive Disorder

Fatemeh Hosseini 1 , Fariba Amini 1 , Seyed Mojtaba Yassini Ardekani 1 , * , Neda Shariat 1 and Mohammad Nadi 1
Authors Information
1 Department of Psychiatry, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: June 28, 2015, 9 (2)
  • Published Online: June 1, 2015
  • Article Type: Original Article
  • Received: May 16, 2014
  • Revised: July 18, 2014
  • Accepted: August 23, 2014
  • DOI: 10.17795/ijpbs1041

To Cite: Hosseini F, Amini F, Yassini Ardekani S M, Shariat N, Nadi M. Double-Blind Randomized Clinical Trial of the Efficacy of Venlafaxine Versus Citalopram in the Treatment of the Acute Phase of Major Depressive Disorder, Iran J Psychiatry Behav Sci. 2015 ; 9(2):-. doi: 10.17795/ijpbs1041.

Copyright © 2015, Mazandaran University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593-602[DOI][PubMed]
  • 2. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008; 23(3): 113-9[DOI][PubMed]
  • 3. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004; 184: 386-92[PubMed]
  • 4. Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7[DOI][PubMed]
  • 5. Practice guideline for the treatment of patients with major depressive disorder. 2010;
  • 6. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, Arias F, Padin J, Martin-Carrasco M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26(6): 1129-34[PubMed]
  • 7. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994; 14(6): 419-23[PubMed]
  • 8. Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009; 259(3): 172-85[DOI][PubMed]
  • 9. Owens MJ, Rosenbaum JF. Escitalopram: a second-generation SSRI. CNS Spectr. 2002; 7(4 Suppl 1): 34-9[PubMed]
  • 10. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000; 58(1): 19-36[PubMed]
  • 11. Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, et al. WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database Syst Rev. 2006; (3)[PubMed]
  • 12. Golden RN, Nicholas L. Antidepressant efficacy of venlafaxine. Depress Anxiety. 2000; 12 Suppl 1: 45-9[PubMed]
  • 13. Sansone RA, Sansone LA. SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder? Innov Clin Neurosci. 2011; 8(6): 10-4[PubMed]
  • 14. de Silva VA, Hanwella R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies. Int Clin Psychopharmacol. 2012; 27(1): 8-16[DOI][PubMed]
  • 15. Gharaii B, Mehryar A, Mehrabi F. [Attribution style in patients with anxiety and depression comorbidity] . Iran J Psychiatry Clin Psychol. 2000; 5(4): 37-43
  • 16. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry. 2004; 19(12): 1123-30[DOI][PubMed]
  • 17. Gibiino S, Marsano A, Serretti A. Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. Int J Neuropsychopharmacol. 2014; 17(1): 1-8[DOI][PubMed]
  • 18. Lapmanee S, Charoenphandhu J, Charoenphandhu N. Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors. Behav Brain Res. 2013; 250: 316-25[DOI][PubMed]
  • 19. Li X, Xing B, Yu E, Chen W, Wu H. The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study. J Neuropsychiatry Clin Neurosci. 2013; 25(2): 157-60[DOI][PubMed]
  • 20. Diaz-Martinez A, Benassinni O, Ontiveros A, Gonzalez S, Salin R, Basquedano G, et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther. 1998; 20(3): 467-76[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments